ANTI- XXXX THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.

@entity1 @entity82 @entity6 @entity7 @entity548 @entity194 @entity4064 @entity1020
PURPOSE: To assess the effect of anti- @entity7 treatment on visual acuity outcome in @entity1 with neovascular age-related @entity1020 presenting with @entity4064 . METHODS: Retrospective analysis of electronic @entity1 care record of 420 eyes treated with ranibizumab between March 2010 and June 2013. The authors classified the extracted sample into 3 categories based on the initial best-corrected visual acuity (BCVA) as measured on the Early Treatment @entity6 Study charts: 0 to 35 letters, 36 to 69 letters, and >= 70 letters. Best BCVA achieved in Year 1, and average BCVA over 36 months was computed. The neovascular lesion type, area of lesion, the presence or absence of @entity548 , retinal pigment epithelium tear, and @entity194 were systematically graded as was extent of @entity82 on a categorical scale of 0 to 4. Regression analysis was performed with the best BCVA achieved in Year 1 as the outcome variable and initial BCVA, @entity1 , and lesion characteristics as explanatory variables. RESULTS: The mean change in BCVA from the initial visit to the best-attained BCVA during Year 1 was highly statistically significant with an improvement of 9.95 letters. The improvement from initial BCVA to average BCVA over 36 months was 4.01 letters. Regression analysis identified @entity194 and @entity82 as predictors of best BCVA, with the model having an r of 0.71. CONCLUSION: Our study supports the use of anti- @entity7 agents even in eyes with low visual acuity particularly when @entity82 and @entity194 are absent and suggests algorithms to predict outcome for combinations of visual acuity and lesion characteristics across the full visual acuity range.
